OppenheimerFunds’s Sage Therapeutics SAGE Stock Holding History

OppenheimerFunds’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$230M	Buy	1,443,145 +4,721	+0.3%	+$684K	0.29%	91
2018 Q4	$138M	Sell	1,438,424 -145,196	-9%	-$16.6M	0.2%	122
2018 Q3	$224M	Sell	1,583,620 -14,547	-0.9%	-$2.25M	0.26%	103
2018 Q2	$250M	Buy	1,598,167 +34,389	+2%	+$5.4M	0.3%	89
2018 Q1	$252M	Buy	1,563,778 +84,247	+6%	+$14.3M	0.31%	84
2017 Q4	$244M	Sell	1,479,531 -314,473	-18%	-$30.5M	0.29%	87
2017 Q3	$112M	Buy	1,794,004 +8,364	+0.5%	+$657K	0.14%	170
2017 Q2	$142M	Buy	1,785,640 +6,401	+0.4%	+$463K	0.18%	148
2017 Q1	$126M	Sell	1,779,239 -156,836	-8%	-$9.19M	0.15%	166
2016 Q4	$98.9M	Buy	1,936,075 +20,201	+1%	+$952K	0.13%	194
2016 Q3	$88.2M	Buy	1,915,874 +1,145,717	+149%	+$46.6M	0.11%	216
2016 Q2	$23.2M	Buy	770,157 +20,591	+3%	+$687K	0.03%	515
2016 Q1	$24M	Buy	+749,566	New	+$26.4M	0.03%	505

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

OppenheimerFunds's SAGE Position: Q1 2019 in Review

OppenheimerFunds increased its Sage Therapeutics (SAGE) stake by 0.33% in Q1 2019, buying an estimated $684K and bringing the position to 1,443,145 shares worth $230M. The position accounts for 0.29% of the portfolio, ranked #91.

OppenheimerFunds first reported a position in SAGE in Q1 2016 and has held it in 13 quarters since. The position peaked at $252M in Q1 2018. 268 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

OppenheimerFunds held 1,443,145 shares of Sage Therapeutics worth $230M as of Q1 2019.
OppenheimerFunds bought 4,721 Sage Therapeutics shares in Q1 2019, an estimated $684K.
Sage Therapeutics made up 0.29% of OppenheimerFunds's portfolio in Q1 2019, its #91 holding.
OppenheimerFunds first reported a position in Sage Therapeutics in Q1 2016 and has held it in 13 quarters since.
OppenheimerFunds's Sage Therapeutics position peaked at $252M in Q1 2018.
268 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.